Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM – Get Rating) – SVB Leerink issued their FY2024 earnings estimates for Mirum Pharmaceuticals in a note issued to investors on Monday, January 23rd. SVB Leerink analyst M. Foroohar anticipates that the company will post earnings of ($0.19) per share for the year. SVB Leerink has a “Outperform” rating and a $39.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($4.01) per share.
MIRM has been the topic of several other reports. Citigroup decreased their price objective on shares of Mirum Pharmaceuticals from $38.00 to $34.00 and set a “buy” rating on the stock in a research note on Thursday, November 10th. HC Wainwright increased their price target on shares of Mirum Pharmaceuticals from $68.00 to $69.00 and gave the company a “buy” rating in a research note on Monday, November 14th. JPMorgan Chase & Co. decreased their price target on shares of Mirum Pharmaceuticals to $30.00 in a research note on Monday, November 28th. Finally, Raymond James decreased their price target on shares of Mirum Pharmaceuticals from $88.00 to $84.00 and set a “strong-buy” rating on the stock in a research note on Tuesday, January 10th.
Mirum Pharmaceuticals Trading Up 4.1 %
Mirum Pharmaceuticals (NASDAQ:MIRM – Get Rating) last issued its quarterly earnings data on Wednesday, November 9th. The company reported ($1.02) earnings per share for the quarter, topping the consensus estimate of ($1.05) by $0.03. The firm had revenue of $18.78 million for the quarter, compared to analysts’ expectations of $21.16 million. Mirum Pharmaceuticals had a negative net margin of 79.72% and a negative return on equity of 99.78%.
Institutional Investors Weigh In On Mirum Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Sandia Investment Management LP acquired a new stake in shares of Mirum Pharmaceuticals during the third quarter worth $46,000. Lazard Asset Management LLC acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter worth $47,000. Legal & General Group Plc raised its holdings in shares of Mirum Pharmaceuticals by 2,193.7% during the second quarter. Legal & General Group Plc now owns 6,583 shares of the company’s stock worth $128,000 after acquiring an additional 6,296 shares during the period. American International Group Inc. raised its holdings in shares of Mirum Pharmaceuticals by 315.7% during the second quarter. American International Group Inc. now owns 7,436 shares of the company’s stock worth $145,000 after acquiring an additional 5,647 shares during the period. Finally, International Biotechnology Trust PLC bought a new position in Mirum Pharmaceuticals in the third quarter valued at $193,000.
Insiders Place Their Bets
In related news, Director Niall O’donnell sold 32,109 shares of the firm’s stock in a transaction on Monday, November 14th. The shares were sold at an average price of $19.60, for a total transaction of $629,336.40. Following the sale, the director now directly owns 1,714,888 shares in the company, valued at $33,611,804.80. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 33.27% of the company’s stock.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O’Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
- Get a free copy of the StockNews.com research report on Mirum Pharmaceuticals (MIRM)
- EVgo Stock is Charged Up to Ride the EV Adoption Wave
- Qualcomm Gets a Boost from Analysts, but is it Time to Buy?
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Can Coty Stock Emerge in 2023 With Upside
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.